Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
230.56
-0.27 (-0.12%)
Jun 22, 2026, 10:46 AM EDT - Market open
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 246.60M EUR in the quarter ending March 31, 2026, with 144.27% growth. This brings the company's revenue in the last twelve months to 865.78M, up 134.82% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
865.78M EUR
Revenue Growth
+134.82%
P/S Ratio
14.45
Revenue / Employee
728,158 EUR
Employees
1,189
Market Cap
14.32B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | 9.05M | 591.57% |
| Dec 31, 2017 | 1.53M | -3.08M | -66.78% |
| Dec 31, 2016 | 4.61M | -3.51M | -43.26% |
| Dec 31, 2015 | 8.12M | -5.87M | -41.94% |
| Dec 31, 2014 | 13.98M | -6.43M | -31.48% |
| Dec 31, 2013 | 20.41M | 4.83M | 30.96% |
| Dec 31, 2012 | 15.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
ASND News
- 8 days ago - Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism - GlobeNewsWire
- 10 days ago - 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism - GlobeNewsWire
- 13 days ago - Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewsWire
- 6 weeks ago - Ascendis Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - Ascendis Pharma Earnings release: Q1 2026 - Filings
- 6 weeks ago - Ascendis Pharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years - GlobeNewsWire
- 7 weeks ago - Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 - GlobeNewsWire